PART I Overview We are a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using our novel cell penetrating peptide (CPP) technology platform. Our lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients a...
Q2 FY2026 — expected 2026-09-25
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-19 | 2025-12-31 | 0001193125-26-115878 | EDGAR | 90K words |
| 2025-03-24 | 2024-12-31 | 0000950170-25-043925 | EDGAR | — |
| 2024-03-14 | 2023-12-31 | 0000950170-24-031529 | EDGAR | — |
| 2023-03-14 | 2022-12-31 | 0000950170-23-007855 | EDGAR | — |
| 2022-03-25 | 2021-12-31 | 0000950170-22-004637 | EDGAR | — |
| 2021-03-04 | 2020-12-31 | 0001564590-21-011003 | EDGAR | — |
| 2020-03-05 | 2019-12-31 | 0001564590-20-008984 | EDGAR | — |
| 2019-03-14 | 2018-12-31 | 0001564590-19-007863 | EDGAR | — |
| 2018-03-09 | 2017-12-31 | 0001193125-18-077456 | EDGAR | — |
| 2017-03-10 | 2016-12-31 | 0001193125-17-078784 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-04 | 2026-06-30 | 0001193125-26-331529 | EDGAR | — |
| 2025-11-05 | 2025-09-30 | 0001193125-25-266969 | EDGAR | 23K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108797 | EDGAR | — |
| 2025-04-30 | 2025-03-31 | 0000950170-25-061222 | EDGAR | — |
| 2024-10-30 | 2024-09-30 | 0000950170-24-119100 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093733 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056965 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0000950170-23-063517 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041293 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0000950170-23-022187 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024223 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016917 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-04 | 0001193125-26-331516 | EDGAR | — |
| 2026-03-19 | 0001193125-26-115119 | EDGAR | 3K words |
| 2026-03-09 | 0001193125-26-098493 | EDGAR | — |
| 2026-02-27 | 0001193125-26-077646 | EDGAR | — |
| 2026-02-24 | 0001193125-26-065186 | EDGAR | — |
| 2026-01-22 | 0001193125-26-018664 | EDGAR | — |
| 2026-01-12 | 0001193125-26-010409 | EDGAR | — |
| 2025-12-17 | 0001193125-25-321738 | EDGAR | — |
| 2025-11-10 | 0001193125-25-273217 | EDGAR | — |
| 2025-11-05 | 0001193125-25-265702 | EDGAR | — |
233 total filings indexed. 201 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001374690 |
| Ticker | LRMR |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.larimartx.com |
| Listed | 2020-05-29 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/LRMR (~200 tokens, structured JSON with cryptographic provenance)